TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7946229
Drug: Behavioural training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural training programme administered by nurses combining life skills training, active encouragement, and a token economy
Study: 22448901
Drug: Anodal TDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodal TDCS (2mA for 20min, 5 daily sessions)
Study: 18079286
Drug: Citalopram (SSRI,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (SSRI, 20 mg/day)
Study: 18079286
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg) as rescue medication
Study: 17313004
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment for ischemic stroke (Control group)
Study: 10972330
Drug: Allogeneic dendritic
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic dendritic cells infusion
Study: 9168216
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo tablet and saline infusion)
Study: 1556523
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g Na2EDTA
Study: 30197148
Drug: Kleb‐SRP vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kleb‐SRP vaccine administered before calving
Study: 30197148
Drug: Kleb‐SRP vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kleb‐SRP vaccine administered after calving
Study: 26865592
Drug: Sf2aWC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sf2aWC vaccine (formalin‐inactivated whole‐cell Shigella flexneri 2a), given orally in three doses (2.6 ± 0.8 × 10(8), × 10(9), × 10(10), and × 10(11)vaccine particles/ml)
Study: 26865592
Drug: Sf2aWC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sf2aWC vaccine
Study: 24488983
Drug: Inotropic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inotropic therapy (dobutamine 43%, dopamine 24%, milrinone 17%, combination 16%)
Study: 16255189
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of Zinacef
Study: 10334653
Drug: Yoghurt enriched
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoghurt enriched with Lactobacillus acidophilus L‐1
Study: 1904120
Drug: Maintenance group
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance group received six weekly instillations of 80 mg of BCG and four additional instillations every three months.
Study: 1904120
Drug: Non-maintenance group
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-maintenance group received six weekly instillations of 80 mg of BCG.
Study: 31822157
Drug: Butylphthalide injection
Normalized name: Butylphthalide
DrugBank: Butylphthalide (DB12749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butylphthalide injection
Study: 26265520
Drug: PolyPill (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: PolyPill (daily single dose consisting of aspirin, valsartan, atorvastatin, and hydrochlorthiazide)
Study: 23766359
Drug: Vandetanib 100
Normalized name: vandetanib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 100 mg/m(2) administered orally, once daily, continuously for 28-day treatment cycles (with possible escalation to 150 mg/m(2)/d after two cycles).
Study: 23766359
Drug: Vandetanib treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib treatment.
Study: 16596105
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate supplementation (0.3 g/kg body mass/day for 5 days)
Study: 1219183
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of synthetic secretin
Study: 1219183
Drug: Pernasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pernasal administration of synthetic secretin (snuff)
Study: 7399873
Drug: Oxprenolol and
Normalized name: oxprenolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol and diuretics for the first eight weeks
Study: 7399873
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus diuretics for the second eight weeks
Study: 7399873
Drug: Diuretics for
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics for the first eight weeks
Study: 7399873
Drug: Diuretics for
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics for the second eight weeks
Study: 7399873
Drug: Oxprenolol and
Normalized name: oxprenolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol and diuretics in reverse order for Group 2
Study: 30545780
Drug: Oral ixazomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ixazomib (3 mg initially, increased to 4 mg from cycle 5 if tolerated)
Study: 30545780
Drug: Oral ixazomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ixazomib
Study: 29607860
Drug: Buccal infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal infiltration anesthesia
Study: 26219614
Drug: Ketamine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (1.5 μg kg min(‐1))
Study: 24439245
Drug: Portal site
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Portal site injections of local anesthetic (Lo group)
Study: 22687265
Drug: Guided self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided self-help cognitive behavioural therapy (CBT) for four weeks
Study: 19604351
Drug: Self administered
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self administered version of the 'Business in Mind' program
Study: 379931
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment complemented by injections of poly A‐poly U
Study: 379931
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment and poly A‐poly U
Study: 30640238
Drug: Cash-based physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cash-based physical therapy
Study: 25978169
Drug: SRT2104 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT2104 (2 g/d for 7 days)
Study: 25978169
Drug: SRT2104 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT2104 (single dose of 2 g)
Study: 25978169
Drug: SRT2104 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT2104 (both single and repeated administration)
Study: 19526798
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) group (group A) - one dose of TCM every day
Study: 19526798
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine group (group B) - subcutaneous injection of low‐molecular‐weight heparins calcium (LMWH)
Study: 15033608
Drug: Angiotensin converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitor therapy (ACEI)
Study: 11597289
Drug: Intravenous antithrombin
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antithrombin III (30,000 IU in total over 4 days)
Study: 11597289
Drug: Intravenous antithrombin
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antithrombin III (30,000 IU in total over 4 days) with concomitant heparin
Study: 11597289
Drug: Placebo (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1% human albumin) with concomitant heparin
Study: 9874886
Drug: Oral PowderJect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PowderJect (OPJ) with powdered lidocaine hydrochloride
Study: 2917116
Drug: No H2-blocker
Normalized name: NO
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No H2-blocker
Study: 15662490
Drug: Duloxetine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (40 mg BID)
Study: 28345387
Drug: Multimodal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal treatment (NF + MED)
Study: 31699651
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia with propofol
Study: 24102295
Drug: Gaming console
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gaming console exercise in addition to usual therapy
Study: 15877932
Drug: scopolamine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: scopolamine (0.4 mg i.m.)
Study: 15877932
Drug: mecamylamine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: mecamylamine (15 mg)
Study: 15877932
Drug: mecamylamine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: mecamylamine (15 mg)/scopolamine (0.4 mg i.m.)
Study: 10389124
Drug: Eperisone hydrochloride
Normalized name: Eperisone hydrochloride
DrugBank: Eperisone (DB08992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eperisone hydrochloride (50 mg t.i.d.)
Study: 8735069
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of noise exposure and exercise for 10 minutes
Study: 1868681
Drug: Cefuroxime prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime prophylaxis (one or three doses)
Study: 2455152
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg p.o.)
Study: 30793412
Drug: Complete stop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete stop of acute medication (programme A)
Study: 30793412
Drug: Restricted intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restricted intake of acute medication (programme B)
Study: 28017399
Drug: High-dose vaccine
Normalized name: Fluzone 2023-2024 high-dose vaccine Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vaccine (1.6 × 10^11 viral particles)
Study: 28017399
Drug: Low-dose vaccine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vaccine (8.0 × 10^10 viral particles)
Study: 28017399
Drug: Placebo (containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (containing only vaccine excipients)
Study: 26053024
Drug: Nalmefene 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 18 mg
Study: 16792582
Drug: Subcutaneous SQ-standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous SQ-standardized specific immunotherapy (SIT)
Study: 8231903
Drug: 0.625 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/day conjugated equine oestrogens (CEE) cyclically + 2.5 mg MPA sequentially for the last 12 days
Study: 8231903
Drug: 50 micrograms/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms/day transdermal oestradiol cyclically + 2.5 mg MPA sequentially for the last 12 days
Study: 8231903
Drug: 0.625 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/day CEE continuously + 2.5 mg MPA sequentially for the last 12 days
Study: 8231903
Drug: 0.625 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/day CEE + 2.5 mg/day MPA continuously
Study: 26905919
Drug: Immediate-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release methylphenidate (n=26) thrice daily (10-20 mg per dose)
Study: 26905919
Drug: Atomoxetine (n=26)
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine (n=26) once daily (0.5-1.2 mg/kg/day)
Study: 24717936
Drug: Acute amphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute amphetamine administration following a sensitizing dosage regime
Study: 23272658
Drug: Regadenoson (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regadenoson (0.4 mg) during CMR stress imaging
Study: 23272658
Drug: Regadenoson (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regadenoson (0.4 mg) during CMR stress imaging without aminophylline
Study: 23272658
Drug: Regadenoson (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regadenoson (0.4 mg) during CMR stress imaging with aminophylline (125 mg)
Study: 16258905
Drug: Milnacipran (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran (active drug)
Study: 12021741
Drug: Brief massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief massage treatment
Study: 10202785
Drug: 8 month,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 month, weekly psychological intervention
Study: 8651088
Drug: Alacepril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alacepril (50 mg)
Study: 1734740
Drug: 5% amobarbital
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% amobarbital solution
Study: 6381169
Drug: Rifamycin SV
Normalized name: rifamycin SV
DrugBank: Rifamycin (DB11753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifamycin SV 250 mg intramuscularly and topical b.i.d.
Study: 6381169
Drug: Neuramide b.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuramide b.i.d. plus other drugs (antibiotics, polivitamins, analgesics, etc.)
Study: 29676689
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen 1000 mg/100 ml every 8 hours for 48 hours
Study: 29676689
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 ml of 0.9% normal saline every 8 hours for 48 hours)
Study: 22998596
Drug: High-volume local
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume local anesthesia (≥7.2 mL, four carpules)
Study: 22998596
Drug: Low-volume local
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume local anesthesia (≤0.9 mL, half a carpule)
Study: 22287203
Drug: Uncontrolled exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncontrolled exercise therapy
Study: 12040953
Drug: Metronidazole 400
Normalized name: metronidazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 400 mg orally twice daily for 2 days
Study: 12040953
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 100 mg orally twice daily for 2 days
Study: 12040953
Drug: BV-negative group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: BV-negative group (no treatment)
Study: 8527349
Drug: Metoprolol CR/ZOK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR/ZOK (100-200 mg once daily)
Study: 6753891
Drug: Atenolol (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50-100 mg once daily)
Study: 1615139
Drug: L-dopa medication
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa medication
Study: 1615139
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of L-dopa medication
Study: 6700850
Drug: Metronidazole (two-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (two-dose perioperative course)
Study: 31211324
Drug: Digoxin pre-treatment
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin pre-treatment
Study: 29538220
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine warm compress (CMWC) combined with WHO 3-step analgesic ladder treatment
Study: 29538220
Drug: WHO 3-step
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHO 3-step analgesic ladder treatment (control group)
Study: 27548072
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg daily for 6 weeks
Study: 27548072
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) as add-on therapy
Study: 24905241
Drug: Classroom-based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classroom-based Cognitive Behaviour Therapy (CBT)
Study: 7619619
Drug: Iohexol 4.5
Normalized name: IOHEXOL 4.5 g ORAL FOR SOLUTION [ORALTAG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iohexol 4.5 mg I/ml
Study: 7619619
Drug: Iohexol 6.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iohexol 6.75 mg I/ml
Study: 7619619
Drug: Iohexol 9
Normalized name: IOHEXOL 9MG/ML ORAL SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iohexol 9 mg I/ml
Study: 1273032
Drug: Talampicillin hydrochloride
Normalized name: Talampicillin hydrochloride
DrugBank: Talampicillin (DB13814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talampicillin hydrochloride (125 mg of ampicillin equivalent, four times daily for six days)
Study: 1273032
Drug: Ampicillin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (250 mg, four times daily for six days)
Study: 29076668
Drug: 6mg dexamethasone
Normalized name: dexamethasone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6mg dexamethasone in 4 doses 12 hours apart (Group A)
Study: 29076668
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses 12 hours apart (Group B)
Study: 25741915
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tenoxicam administered three times by weekly intervals
Study: 25741915
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg methylprednisolone acetate administered just once
Study: 19238125
Drug: Serotonin-norepinephrine reuptake
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin-norepinephrine reuptake inhibitor (SNRI)
Study: 19238125
Drug: Augmentation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation treatment
Study: 16931634
Drug: Peak flow
Normalized name: Peak Flow Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak flow monitoring (twice daily or as needed)
Study: 15324523
Drug: Adjustable dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustable dosing (budesonide/formoterol 1 inhalation b.i.d.; stepping up to 2 or 4 inhalations b.i.d. if asthma worsened)
Study: 15324523
Drug: Fixed dosing
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dosing (budesonide/formoterol 2 inhalations b.i.d.)
Study: 3015543
Drug: sequential intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: sequential intermittent polychemotherapy (sq.CT) of 3 different alternating drug combinations given intermittently over 1 year
Study: 3015543
Drug: 4-drug combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-drug combination chemotherapy (CT) given intermittently over 3 years
Study: 31486624
Drug: 10 mL/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL/kg/h rate 5% Dextrose infusion preoperatively for 30 minutes, followed by Ringer's lactate until the end of surgery (Group P)
Study: 31486624
Drug: 10 mL/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL/kg/h rate of Ringer's lactate preoperatively for 30 minutes and 5% Dextrose during the operation (Group I)
Study: 31486624
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate solution infusion at a rate of 10 mL/kg/h (Group C)
Study: 31486624
Drug: 10 mL/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL/kg/h rate 5% Dextrose infusion preoperatively for 30 minutes (Group P)
Study: 23545346
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg spinal morphine
Study: 23545346
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg spinal morphine
Study: 19636702
Drug: Sequential docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential docetaxel (100 mg/m(2)) followed by epirubicin (75 mg/m(2)) plus cyclophosphamide (700 mg/m(2))
Study: 19636702
Drug: FEC regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC regimen (epirubicin 75 mg/m(2), cyclophosphamide 700 mg/m(2), and 5-fluorouracil 700 mg/m(2))
Study: 19636702
Drug: Neutropenia requiring
Normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutropenia requiring administration of granulocyte colony-stimulating factor
Study: 10587287
Drug: Deprenyl 15
Normalized name: (11C)L-deprenyl-D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deprenyl 15 mg/day
Study: 8732386
Drug: 0.08 ml.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.08 ml.kg‐1 Albunex
Study: 8732386
Drug: 0.22 ml.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.22 ml.kg‐1 Albunex
Study: 8732386
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml albumin
Study: 6315259
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propranolol (160 mg daily) and verapamil (360 mg daily)
Study: 6359843
Drug: Verapamil (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (360 mg daily)
Study: 6315259
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propranolol and verapamil
Study: 3732715
Drug: Propranolol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (160 mg daily)
Study: 29262811
Drug: Nutrition and
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition and Culinary in the Kitchen program (3-hour weekly classes for 6 weeks, including hands-on cooking and a market tour)
Study: 23681836
Drug: Magnesium isoglycyrrhizinate
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium isoglycyrrhizinate (MI) 100 mg intravenously for 4 days
Study: 15723746
Drug: Lean System
Normalized name: Lophophytum leandrii extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lean System 7 (commercial weight-loss product), 3 capsules twice daily for 8 weeks